NYSE$OSCR

Oscar Health Inc · Q4 2022 earnings

Q4 2022 earnings · · Investor relations

Briefing

Oscar Health's financial performance showed improvement in core operating margins and key metrics.

Oscar Health's Q4 2022 results demonstrated significant year-over-year improvement in core operating margins. The company's focus on cost management and administrative efficiency has positioned it well for future profitability.

  • Membership increased by 93% year-over-year, reaching 1,151,483 members as of December 31, 2022.
  • The InsuranceCo Combined Ratio improved by approximately 5 points year-over-year.
  • Oscar Health is introducing its outlook for 2023 with an anticipated InsuranceCo Combined Ratio at or less than 100%.
  • The company anticipates Direct and Assumed Policy Premiums of $6.4 billion to $6.6 billion for 2023.

Headline financials

Total Revenue

$995M

Previous: $496M+100.6%
EPS (adj)

-$1.05

Previous: -$0.95-10.5%
Medical loss ratio

91.6%

Previous: 97.9%-6.4%
Net Income

-$227M

Previous: -$198M-14.6%
Operating Income

-$222M

Previous: -$196M-13.4%
Gross Profit

$1.04B

Previous: $520M+99.4%
Cash & Equivalents

$1.56B

Previous: $1.1B+41.2%
Total Assets

$4.53B

Previous: $3.32B+36.3%
Stock-Based Comp

$29.1M

Previous: $28.3M+2.9%

Revenue & EPS history

Oscar Health · Revenue · Quarterly

$995M

Q4 2022+100.6%vs Q4 2021
Beat estimate in 5 of 15 quarters(33%)
ActualEstimate

Forward guidance

The Company is introducing its outlook for 2023 including anticipated Direct and Assumed Policy Premiums of $6.4 billion to $6.6 billion, an InsuranceCo Combined Ratio at or less than 100%, and a significantly improved Adjusted EBITDA loss of ($175) million to ($75) million.

Tailwinds

  • Direct and Assumed Policy Premiums of $6,400,000 to $6,600,000
  • Medical Loss Ratio of 82% to 84%
  • InsuranceCo Administrative Expense Ratio of 17% to 18%
  • InsuranceCo Adjusted EBITDA of $20,000 to $120,000
  • Adjusted Administrative Expense Ratio of 20.5% to 21.5%

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q4 2022

Historical avgQ4 2022

+3.7%

Avg return

Earnings day

+5.6%

Avg return

5 days after

+7.5%

Avg return

30 days after

64%

16 / 25 earnings

Positive

+30.0%

Q1 2025

Best reaction

-23.9%

Q3 2022

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+2.7%+22.6%+36.6%
Q4 2025+1.7%+6.0%+2.7%
Q3 2025-2.8%-12.8%-1.5%
Q1 2025+30.0%+28.7%+18.0%
Q4 2024+3.1%-3.7%+4.5%
Q3 2024-12.9%-12.8%+0.4%
Q2 2024+7.2%+4.4%-1.4%
Q1 2024+9.3%+14.1%+2.8%
Q4 2023+22.7%+27.5%+7.7%
Q3 2023+23.5%+24.5%+42.0%
Q2 2023+8.6%+1.9%-10.5%
Q1 2023-8.8%-6.6%+17.8%
Q4 2022+21.0%+36.2%-3.9%
Q3 2022-23.9%-4.5%-11.3%
Q2 2022+19.9%+21.1%-3.7%
Q1 2022-8.9%-2.0%-25.0%
Q4 2019+6.3%+2.5%+39.1%
Q4 2021+2.4%+15.6%+21.9%
Q3 2020-2.4%-6.3%-12.7%
Q3 2021-23.3%-25.2%-33.0%
Q2 2020-16.4%-11.8%+19.4%
Q2 2021-0.9%-12.0%+17.9%
Q4 2020+15.2%+14.5%+23.1%
Q1 2020+15.2%+14.5%+23.1%
Q1 2021+3.6%+4.2%+14.0%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro